首页 > 最新文献

Taehan Kan Hakhoe chi = The Korean journal of hepatology最新文献

英文 中文
[Direct analysis of HBV-specific CD8+ lymphocyte by tetrameric HLA-A2/core 18-27 complex in chronic Hepatitis B]. [用四聚体HLA-A2/core 18-27复合物直接分析慢性乙型肝炎患者hbv特异性CD8+淋巴细胞]。
Chun Kyon Lee, Jeong Hun Suh, Young Suk Cho, Kwang Hyub Han, Jae Bock Chung, Chae Yoon Chon, Young Myoung Moon

Background/aims: Hepatitis B virus(HBV) specific cytotoxic T lymphocyte (CTL) response is believed to play a major role in virus control and liver damage in chronic hepatitis B(CHB). We performed this study to evaluate whether HBV specific CTL could be visualized directly by tetrameric HLA-A2/core 18-27 complex(T c18-27) in the peripheral blood and liver of patients with CHB. On the basis of our results we clarified patients intrahepatic compartmentalization and correlation with HBV specific CTL and viral replication or liver damage.

Methods: We stained peripheral blood mononuclear cells of 33 HLA-A2 + and 8 HLA-A2 patients with CHB with cytochrome conjugated anti-CD8 mAb and phycoerythrin conjugated T c18-27. Among these we analysed intrahepatic lymphocyte of 11 HLA-A2 + patients. We compared the frequency of T c18-27 specific CD8+ cells with serum HBV-DNA levels or alanine aminotransferase(ALT) levels.

Results: The frequency of circulating T c18-27 specific CD8+ cell was higher(9-101 cells per 50,000 CD8+ cells) than background level in 14 among 33 patients. The frequency of intrahepatic T c18-27 specific CD8+ cells was 12-2100 cells per 50,000 CD8+ cells in 8 out of 11 patients whose liver was obtained This was 17.4-150 times higher than circulating T c18-27 specific CD8+ cells. The frequency of circulating T c18-27 specific CD8+ cells was increased in 10 out of 18 patients with serum HBV DNA level <0.5 pg/mL and ALT < 40 IU/L. It was increased in just 4 out of 15 patients with HBV DNA level > 800 pg/mL and ALT > 70 IU/L. The frequency of intrahepatic T c18-27 CTL tended to be lower in high levels of serum HBV DNA and was not correlated with liver inflammation.

Conclusion: This study proves that if HBV-specific CTLs are barely detectable in the peripheral blood of CHB, much more HBV-specific CTLs are in the liver and most HBV-specific CTLs are infiltrated in the liver. Also, in the presence of an effective HBV specific CD8 response the inhibition of viral replication can be independent of liver damage.

背景/目的:乙型肝炎病毒(HBV)特异性细胞毒性T淋巴细胞(CTL)反应被认为在慢性乙型肝炎(CHB)的病毒控制和肝损伤中起重要作用。我们进行了这项研究,以评估HBV特异性CTL是否可以通过CHB患者外周血和肝脏中的四聚体HLA-A2/core 18-27复合物(tc18 -27)直接可视化。在我们的研究结果的基础上,我们澄清了患者肝内区室化及其与HBV特异性CTL和病毒复制或肝损伤的相关性。方法:用细胞色素偶联抗cd8单抗和植红蛋白偶联tc18 -27对33例HLA-A2 +和8例HLA-A2 CHB患者外周血单个核细胞进行染色。其中,我们分析了11例HLA-A2 +患者的肝内淋巴细胞。我们比较了tc18 -27特异性CD8+细胞的频率与血清HBV-DNA水平或谷丙转氨酶(ALT)水平。结果:33例患者中有14例循环T c18-27特异性CD8+细胞的频率高于背景水平(每5万个CD8+细胞中有9-101个细胞)。在获得肝脏的11名患者中,有8名患者的肝内T c18-27特异性CD8+细胞的频率为每50,000个CD8+细胞中12-2100个细胞,这比循环T c18-27特异性CD8+细胞高17.4-150倍。在18例血清HBV DNA水平为800 pg/mL、ALT > 70 IU/L的患者中,有10例循环T c18-27特异性CD8+细胞的频率增加。在高水平的血清HBV DNA中,肝内T c18-27 CTL的频率往往较低,与肝脏炎症无关。结论:本研究证明,如果CHB外周血中几乎检测不到hbv特异性ctl,则肝脏中hbv特异性ctl更多,并且大多数hbv特异性ctl浸润在肝脏中。此外,在存在有效的HBV特异性CD8应答的情况下,病毒复制的抑制可以独立于肝损伤。
{"title":"[Direct analysis of HBV-specific CD8+ lymphocyte by tetrameric HLA-A2/core 18-27 complex in chronic Hepatitis B].","authors":"Chun Kyon Lee,&nbsp;Jeong Hun Suh,&nbsp;Young Suk Cho,&nbsp;Kwang Hyub Han,&nbsp;Jae Bock Chung,&nbsp;Chae Yoon Chon,&nbsp;Young Myoung Moon","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Hepatitis B virus(HBV) specific cytotoxic T lymphocyte (CTL) response is believed to play a major role in virus control and liver damage in chronic hepatitis B(CHB). We performed this study to evaluate whether HBV specific CTL could be visualized directly by tetrameric HLA-A2/core 18-27 complex(T c18-27) in the peripheral blood and liver of patients with CHB. On the basis of our results we clarified patients intrahepatic compartmentalization and correlation with HBV specific CTL and viral replication or liver damage.</p><p><strong>Methods: </strong>We stained peripheral blood mononuclear cells of 33 HLA-A2 + and 8 HLA-A2 patients with CHB with cytochrome conjugated anti-CD8 mAb and phycoerythrin conjugated T c18-27. Among these we analysed intrahepatic lymphocyte of 11 HLA-A2 + patients. We compared the frequency of T c18-27 specific CD8+ cells with serum HBV-DNA levels or alanine aminotransferase(ALT) levels.</p><p><strong>Results: </strong>The frequency of circulating T c18-27 specific CD8+ cell was higher(9-101 cells per 50,000 CD8+ cells) than background level in 14 among 33 patients. The frequency of intrahepatic T c18-27 specific CD8+ cells was 12-2100 cells per 50,000 CD8+ cells in 8 out of 11 patients whose liver was obtained This was 17.4-150 times higher than circulating T c18-27 specific CD8+ cells. The frequency of circulating T c18-27 specific CD8+ cells was increased in 10 out of 18 patients with serum HBV DNA level <0.5 pg/mL and ALT < 40 IU/L. It was increased in just 4 out of 15 patients with HBV DNA level > 800 pg/mL and ALT > 70 IU/L. The frequency of intrahepatic T c18-27 CTL tended to be lower in high levels of serum HBV DNA and was not correlated with liver inflammation.</p><p><strong>Conclusion: </strong>This study proves that if HBV-specific CTLs are barely detectable in the peripheral blood of CHB, much more HBV-specific CTLs are in the liver and most HBV-specific CTLs are infiltrated in the liver. Also, in the presence of an effective HBV specific CD8 response the inhibition of viral replication can be independent of liver damage.</p>","PeriodicalId":85610,"journal":{"name":"Taehan Kan Hakhoe chi = The Korean journal of hepatology","volume":"8 2","pages":"139-48"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22169754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Ultrastructure of chronic liver diseases: endothelial cells of the hepatic sinusoids]. [慢性肝病的超微结构:肝窦内皮细胞]。
Kyu Won Chung
{"title":"[Ultrastructure of chronic liver diseases: endothelial cells of the hepatic sinusoids].","authors":"Kyu Won Chung","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":85610,"journal":{"name":"Taehan Kan Hakhoe chi = The Korean journal of hepatology","volume":"8 2","pages":"231-44"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22170894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The usefullness of percutaneous transluminal balloon angioplasty in the management of budd-Chiari syndrome]. [经皮腔内球囊血管成形术在budd-Chiari综合征治疗中的应用]。
Se Hwan Kim, Kyung Sool Yu, Seung Min Baek, Seung Yup Lee, Hyun Su Kim, Won Young Tak, Young Oh Kweon, Sung Kook Kim, Yong Hwan Choi, Joon Mo Chung

Background/aims: Membranous obstruction is the most common cause of Budd-Chiari syndrome in Orientals. Recently, percutaneous transluminal balloon angioplasty (PTBA) has been successfully applied as a treatment of membranous obstruction. We evaluated etiologies and clinical manifestations in our cases and the usefulness of PTBA.

Methods: Twelve cases of Budd-Chiari syndrome were analyzed.

Results: 50.3 years was the average age of the cases (ranging from 37 to 67 years). Major symptoms or signs were superficial collateral vessels on the chest or the abdomen in 6 cases, ascites in 3, abdominal pain in 4, hepatomegaly in 4, splenomegaly in 3, melena or hematemesis in 2, and leg edema in 2. Upper gastrointestinal endoscopy showed esophageal varices in 6 cases and two of these 6 cases had gastric varices. Of 8 cases with liver cirrhosis, 4 were classified as Child-Pugh class A and 4 as B. Four patients with cirrhosis had concurrent hepatocellular carcinoma including 1 patient who was HBs Ag positive. Etiologies were membranous obstruction in 11 cases and protein C deficiency in 1 case. The main site of obstruction was IVC in 8 and hepatic vein in 4. PTBA was successfully performed in 8 cases of membranous obstruction. During the mean follow-up period of 27.6 months (12-40 months), there were no reobstructions except in 2 cases.

Conclusions: The most common cause of Budd-Chiari syndrome in our cases was membranous obstruction of IVC. Percutaneous transluminal balloon angioplasty is a very useful treatment method.

背景/目的:膜性梗阻是东方人Budd-Chiari综合征最常见的病因。近年来,经皮腔内球囊血管成形术(PTBA)已成功应用于治疗膜性梗阻。我们评估了病例的病因和临床表现以及PTBA的有效性。方法:对12例Budd-Chiari综合征进行分析。结果:患者平均年龄50.3岁(37 ~ 67岁)。主要症状或体征为胸、腹浅侧支血管6例,腹水3例,腹痛4例,肝肿大4例,脾肿大3例,黑黑或呕血2例,腿部水肿2例。上消化道内镜检查发现食管静脉曲张6例,其中2例胃静脉曲张。8例肝硬化患者中Child-Pugh A级4例,b级4例。4例肝硬化患者合并肝细胞癌,其中1例HBs Ag阳性。病因为膜性梗阻11例,蛋白C缺乏1例。梗阻部位主要为下腔静脉8例,肝静脉4例。PTBA成功治疗8例膜性梗阻。在平均27.6个月(12 ~ 40个月)的随访中,除2例外,未发生梗阻。结论:我们病例中最常见的原因是下腔静脉膜性梗阻。经皮腔内球囊血管成形术是一种非常有用的治疗方法。
{"title":"[The usefullness of percutaneous transluminal balloon angioplasty in the management of budd-Chiari syndrome].","authors":"Se Hwan Kim,&nbsp;Kyung Sool Yu,&nbsp;Seung Min Baek,&nbsp;Seung Yup Lee,&nbsp;Hyun Su Kim,&nbsp;Won Young Tak,&nbsp;Young Oh Kweon,&nbsp;Sung Kook Kim,&nbsp;Yong Hwan Choi,&nbsp;Joon Mo Chung","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Membranous obstruction is the most common cause of Budd-Chiari syndrome in Orientals. Recently, percutaneous transluminal balloon angioplasty (PTBA) has been successfully applied as a treatment of membranous obstruction. We evaluated etiologies and clinical manifestations in our cases and the usefulness of PTBA.</p><p><strong>Methods: </strong>Twelve cases of Budd-Chiari syndrome were analyzed.</p><p><strong>Results: </strong>50.3 years was the average age of the cases (ranging from 37 to 67 years). Major symptoms or signs were superficial collateral vessels on the chest or the abdomen in 6 cases, ascites in 3, abdominal pain in 4, hepatomegaly in 4, splenomegaly in 3, melena or hematemesis in 2, and leg edema in 2. Upper gastrointestinal endoscopy showed esophageal varices in 6 cases and two of these 6 cases had gastric varices. Of 8 cases with liver cirrhosis, 4 were classified as Child-Pugh class A and 4 as B. Four patients with cirrhosis had concurrent hepatocellular carcinoma including 1 patient who was HBs Ag positive. Etiologies were membranous obstruction in 11 cases and protein C deficiency in 1 case. The main site of obstruction was IVC in 8 and hepatic vein in 4. PTBA was successfully performed in 8 cases of membranous obstruction. During the mean follow-up period of 27.6 months (12-40 months), there were no reobstructions except in 2 cases.</p><p><strong>Conclusions: </strong>The most common cause of Budd-Chiari syndrome in our cases was membranous obstruction of IVC. Percutaneous transluminal balloon angioplasty is a very useful treatment method.</p>","PeriodicalId":85610,"journal":{"name":"Taehan Kan Hakhoe chi = The Korean journal of hepatology","volume":"8 2","pages":"179-88"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22170887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rhus-chicken. Rhus鸡肉。
Byung Min Ahn
{"title":"Rhus-chicken.","authors":"Byung Min Ahn","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":85610,"journal":{"name":"Taehan Kan Hakhoe chi = The Korean journal of hepatology","volume":"8 2","pages":"245-7"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22170895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The clinical significance of quantitation of HBV DNA in serum-comparison of the branched-DNA assay with the second-generation digene hybrid capture assay and long-term observation]. 【血清中HBV DNA定量的临床意义——支链DNA法与二代基因杂交捕获法的比较及长期观察】。
Eun Jung Jun, Joon Yeol Han, Hwang Choi, U Im Chang, Tae Kyu Lee, Young Hwan Kim, Jin Il Kim, Soo Heon Park, Jae Kwang Kim, Kyu Won Chung, Hee Sik Sun

Background/aims: Serum levels of hepatitis B virus (HBV) DNA are direct measures of viral replication in hepatocytes. We compared branched-DNA assay (Quantiplex(TM), bDNA) and Hybridization Capture II (HCII), and evaluated the clinical significance of HBV DNA quantitation in the natural course of HBV infection.

Methods: We analyzed results of bDNA in 324 serum samples from 83 untreated male patients with chronic hepatitis B. Mean follow up period was 11.8 years. HCII was also performed in 157 arbitrarily selected samples.

Results: HBV DNA levels measured with two assays were very similar (r(2)=0.893, p<0.0001). HBV DNA detection rate of HCII was 6.4% higher than that of bDNA in HBeAg positive samples. HBV DNA detection rate was higher in cases with higher ALT. Among 73 patients with initial diagnosis of chronic hepatitis, 38 patients (52.1%) experienced progression to cirrhosis, and hepatocellular carcinoma (HCC) was developed in 9 (12.3%). HCC was developed in 5 (50.0%) of 10 patients with initial diagnosis of cirrhosis. While HBeAg positive rates during chronic hepatitis, cirrhosis and HCC were 57.8%, 55.0% and 14.3%, respectively (p=0.006), HBV DNA detection rates were 70.6%, 64.0% and 42.9%, respectively (p=0.08). Especially in HCC, the discrepancy between HBeAg positive rate and HBV DNA detection rate may suggest the appearance of variants which cannot produce HBeAg.

Conclusion: Both HCII and bDNA were similar HBV DNA quantitation assays for clinical use. HBV DNA level correlated with the severity of liver disease. Screening tests for HCC should be recommended in patients whose HBeAg is negative and have detectable HBV DNA.

背景/目的:血清乙型肝炎病毒(HBV) DNA水平是肝细胞中病毒复制的直接指标。我们比较了支链DNA测定法(Quantiplex(TM), bDNA)和杂交捕获II (HCII),并评价了HBV DNA定量在HBV感染自然过程中的临床意义。方法:对83例未经治疗的男性慢性乙型肝炎患者324份血清bDNA进行分析,平均随访11.8年。在157个随机选择的样本中进行HCII。结果:两种方法测定的HBV DNA水平非常相似(r(2)=0.893)。结论:HCII和bDNA是临床应用的相似的HBV DNA定量方法。HBV DNA水平与肝病严重程度相关。建议对HBeAg阴性且HBV DNA可检测的患者进行HCC筛查。
{"title":"[The clinical significance of quantitation of HBV DNA in serum-comparison of the branched-DNA assay with the second-generation digene hybrid capture assay and long-term observation].","authors":"Eun Jung Jun,&nbsp;Joon Yeol Han,&nbsp;Hwang Choi,&nbsp;U Im Chang,&nbsp;Tae Kyu Lee,&nbsp;Young Hwan Kim,&nbsp;Jin Il Kim,&nbsp;Soo Heon Park,&nbsp;Jae Kwang Kim,&nbsp;Kyu Won Chung,&nbsp;Hee Sik Sun","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Serum levels of hepatitis B virus (HBV) DNA are direct measures of viral replication in hepatocytes. We compared branched-DNA assay (Quantiplex(TM), bDNA) and Hybridization Capture II (HCII), and evaluated the clinical significance of HBV DNA quantitation in the natural course of HBV infection.</p><p><strong>Methods: </strong>We analyzed results of bDNA in 324 serum samples from 83 untreated male patients with chronic hepatitis B. Mean follow up period was 11.8 years. HCII was also performed in 157 arbitrarily selected samples.</p><p><strong>Results: </strong>HBV DNA levels measured with two assays were very similar (r(2)=0.893, p<0.0001). HBV DNA detection rate of HCII was 6.4% higher than that of bDNA in HBeAg positive samples. HBV DNA detection rate was higher in cases with higher ALT. Among 73 patients with initial diagnosis of chronic hepatitis, 38 patients (52.1%) experienced progression to cirrhosis, and hepatocellular carcinoma (HCC) was developed in 9 (12.3%). HCC was developed in 5 (50.0%) of 10 patients with initial diagnosis of cirrhosis. While HBeAg positive rates during chronic hepatitis, cirrhosis and HCC were 57.8%, 55.0% and 14.3%, respectively (p=0.006), HBV DNA detection rates were 70.6%, 64.0% and 42.9%, respectively (p=0.08). Especially in HCC, the discrepancy between HBeAg positive rate and HBV DNA detection rate may suggest the appearance of variants which cannot produce HBeAg.</p><p><strong>Conclusion: </strong>Both HCII and bDNA were similar HBV DNA quantitation assays for clinical use. HBV DNA level correlated with the severity of liver disease. Screening tests for HCC should be recommended in patients whose HBeAg is negative and have detectable HBV DNA.</p>","PeriodicalId":85610,"journal":{"name":"Taehan Kan Hakhoe chi = The Korean journal of hepatology","volume":"8 2","pages":"157-66"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22169756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oromucosal cytokine therapy: mechanism(s) of action. 口腔粘膜细胞因子治疗:作用机制。
Michael G Tovey

Oromucosal cytokine therapy allows large amounts of cytokines to be administered with improved outcome and without dose limiting toxicity. Orally administered cytokines exert their effects by a novel two pronged mechanism of action. Firstly, specific populations of immuno-competent effector cells are activated in the oral cavity and migrate to the site of virus replication. Secondly, chemokines produced in the lymphoid tissue of the oral cavity enter the peripheral circulation and redirect activated lymphocytes to eliminate virus infected cells. Oromucosal IFN therapy constitutes an alternative and improved means of therapy for diseases such as chronic viral hepatitis which are currently treated parenterally with IFN alpha. The oral route also has obvious advantages for ease of administration and improved patient compliance. Furthermore, the availability of a well tolerated form of IFN therapy will also allow Type I IFNs to be used for the treatment of diseases such as upper respiratory tract virus infections, for which parenteral IFN therapy is currently precluded due to unacceptable toxicity.

口粘膜细胞因子治疗允许大量细胞因子的施用,改善了结果,没有剂量限制的毒性。口服细胞因子通过一种新的双管齐下的作用机制发挥其作用。首先,特定的免疫活性效应细胞群在口腔内被激活,并迁移到病毒复制的部位。其次,在口腔淋巴组织中产生的趋化因子进入外周循环,重新引导活化的淋巴细胞消除病毒感染的细胞。口黏膜干扰素治疗是慢性病毒性肝炎等疾病的一种替代和改进的治疗手段,目前这些疾病是通过肠外注射干扰素治疗的。口服途径在易于给药和提高患者依从性方面也有明显的优势。此外,一种耐受性良好的干扰素治疗形式的可用性也将使I型干扰素用于治疗上呼吸道病毒感染等疾病,由于无法接受的毒性,目前无法使用肠外干扰素治疗。
{"title":"Oromucosal cytokine therapy: mechanism(s) of action.","authors":"Michael G Tovey","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Oromucosal cytokine therapy allows large amounts of cytokines to be administered with improved outcome and without dose limiting toxicity. Orally administered cytokines exert their effects by a novel two pronged mechanism of action. Firstly, specific populations of immuno-competent effector cells are activated in the oral cavity and migrate to the site of virus replication. Secondly, chemokines produced in the lymphoid tissue of the oral cavity enter the peripheral circulation and redirect activated lymphocytes to eliminate virus infected cells. Oromucosal IFN therapy constitutes an alternative and improved means of therapy for diseases such as chronic viral hepatitis which are currently treated parenterally with IFN alpha. The oral route also has obvious advantages for ease of administration and improved patient compliance. Furthermore, the availability of a well tolerated form of IFN therapy will also allow Type I IFNs to be used for the treatment of diseases such as upper respiratory tract virus infections, for which parenteral IFN therapy is currently precluded due to unacceptable toxicity.</p>","PeriodicalId":85610,"journal":{"name":"Taehan Kan Hakhoe chi = The Korean journal of hepatology","volume":"8 2","pages":"125-31"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22169752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A study of polymorphism in UDP-glucuronosyltransferase 1 (UGT-1A1) promoter gene in Korean patients with Gilbert's syndrome]. 【韩国Gilbert综合征患者udp -葡萄糖醛酸糖基转移酶1 (UGT-1A1)启动子基因多态性研究】。
Yoon Hong Kim, Jong Eun Yeon, Gil Man Jung, Hyo Jung Kim, Jae Seon Kim, Kwan Soo Byun, Young Tae Bak, Chang Hong Lee

Background/aims: Hepatic glucuronidating activity, essential for efficient biliary excretion of bilirubin, is reduced to about 30 percent of normal in patients with Gilbert's syndrome. Patients with Gilbert's syndrome have an additional TA insertion in the A(TA)TAA of UDP-glucuronosyltransferase 1 (UGT-1A1) promoter gene. This results in reduced frequency and accuracy of transcription initiation and enzyme activity. The frequency and location of the mutation vary according to races. This study was done to determine the UGT-1A1 promoter gene mutation in Korean cases of Gilbert's syndrome.

Methods: Promoter regions of the gene for bilirubin UGT-1A1 in twelve patients with Gilbert's syndrome and twenty healthy subjects (controls) were sequenced.

Results: 1) Among twelve Gilbert's syndrome five patients were homozygous for A(TA)6/6TAA, two were homozygous for A(TA)7/7TAA, and the other five were heterozygous for A(TA)6/7TAA. The prevalence of A(TA)TAA mutation was 58.3 percent. 2) Among twenty healthy subjects seventeen were homozygous for A(TA)6/6TAA, one was homozygous for A(TA)7/7TAA, and two were heterozygous for A(TA)6/7TAA. The prevalence of A(TA)TAA mutation was 15 percent. 3) The prevalence of A(TA)TAA mutation in Gilbert's syndrome patients was significantly higher than in the controls (p=0.018).

Conclusion: Although the prevalence of A(TA)TAA mutation in Korean patients with Gilbert's syndrome is significantly higher than in the controls, the mutations of the promoter region of UGT-1A1 gene appear not to be the main or sole cause in Gilbert's syndrome in Korea since the prevalence of A(TA)TAA mutation is not so high. Further studies to determine the relationship between other UGT-1A1 gene mutation and Gilbert's syndrome in Korea are needed.

背景/目的:对于胆红素的有效胆汁排泄至关重要的肝糖醛酸化活性,在吉尔伯特综合征患者中降低到正常水平的30%左右。吉尔伯特综合征患者在udp -葡萄糖醛酸糖基转移酶1 (UGT-1A1)启动子基因的A(TA)TAA中有一个额外的TA插入。这导致转录起始和酶活性的频率和准确性降低。突变的频率和位置因种族而异。这项研究是为了确定韩国吉尔伯特综合征患者的UGT-1A1启动子基因突变。方法:对12例吉尔伯特综合征患者和20例正常人(对照)的胆红素UGT-1A1基因启动子区进行测序。结果:1)12例Gilbert综合征患者中A(TA)6/6TAA纯合5例,A(TA)7/7TAA纯合2例,A(TA)6/7TAA杂合5例。A(TA)TAA突变的患病率为58.3%。2) 20例健康受试者中,A(TA)6/6TAA纯合子17例,A(TA)7/7TAA纯合子1例,A(TA)6/7TAA杂合子2例。A(TA)TAA突变的患病率为15%。3) Gilbert综合征患者A(TA)TAA突变发生率显著高于对照组(p=0.018)。结论:虽然韩国Gilbert's综合征患者A(TA)TAA突变的发生率明显高于对照组,但UGT-1A1基因启动子区突变似乎不是韩国Gilbert's综合征的主要或唯一原因,因为韩国Gilbert's综合征患者A(TA)TAA突变的发生率并不高。需要进一步研究其他UGT-1A1基因突变与韩国吉尔伯特综合征的关系。
{"title":"[A study of polymorphism in UDP-glucuronosyltransferase 1 (UGT-1A1) promoter gene in Korean patients with Gilbert's syndrome].","authors":"Yoon Hong Kim,&nbsp;Jong Eun Yeon,&nbsp;Gil Man Jung,&nbsp;Hyo Jung Kim,&nbsp;Jae Seon Kim,&nbsp;Kwan Soo Byun,&nbsp;Young Tae Bak,&nbsp;Chang Hong Lee","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Hepatic glucuronidating activity, essential for efficient biliary excretion of bilirubin, is reduced to about 30 percent of normal in patients with Gilbert's syndrome. Patients with Gilbert's syndrome have an additional TA insertion in the A(TA)TAA of UDP-glucuronosyltransferase 1 (UGT-1A1) promoter gene. This results in reduced frequency and accuracy of transcription initiation and enzyme activity. The frequency and location of the mutation vary according to races. This study was done to determine the UGT-1A1 promoter gene mutation in Korean cases of Gilbert's syndrome.</p><p><strong>Methods: </strong>Promoter regions of the gene for bilirubin UGT-1A1 in twelve patients with Gilbert's syndrome and twenty healthy subjects (controls) were sequenced.</p><p><strong>Results: </strong>1) Among twelve Gilbert's syndrome five patients were homozygous for A(TA)6/6TAA, two were homozygous for A(TA)7/7TAA, and the other five were heterozygous for A(TA)6/7TAA. The prevalence of A(TA)TAA mutation was 58.3 percent. 2) Among twenty healthy subjects seventeen were homozygous for A(TA)6/6TAA, one was homozygous for A(TA)7/7TAA, and two were heterozygous for A(TA)6/7TAA. The prevalence of A(TA)TAA mutation was 15 percent. 3) The prevalence of A(TA)TAA mutation in Gilbert's syndrome patients was significantly higher than in the controls (p=0.018).</p><p><strong>Conclusion: </strong>Although the prevalence of A(TA)TAA mutation in Korean patients with Gilbert's syndrome is significantly higher than in the controls, the mutations of the promoter region of UGT-1A1 gene appear not to be the main or sole cause in Gilbert's syndrome in Korea since the prevalence of A(TA)TAA mutation is not so high. Further studies to determine the relationship between other UGT-1A1 gene mutation and Gilbert's syndrome in Korea are needed.</p>","PeriodicalId":85610,"journal":{"name":"Taehan Kan Hakhoe chi = The Korean journal of hepatology","volume":"8 2","pages":"132-8"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22169753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Laparoscopic and percutaneous ultrasound guided radiofrequency ablation for hepatocellular carcinoma: a preliminary study]. [腹腔镜和经皮超声引导射频消融术治疗肝细胞癌的初步研究]。
Min Kyu Jung, Jong Hyup Lee, Tae Seok Kim, Hyun Soo Kim, Chang Min Cho, Won Young Tak, Young Oh Kweon, Sung Kook Kim, Yong Hwan Choi, Joon Mo Chung

Background/aims: Radiofrequency ablation (RFA) is emerging as a new therapeutic method in the management of hepatocellular carcinoma (HCC). We report the results of 64 patients with a follow-up interval of 3 to 19 months.

Method: Sixty-four patients with 82 nodules underwent ultrasound guided RFA. The mean tumor diameter was 2.5+/-1.0 cm. Laparoscopic ultrasound guided RFA was performed in 38 cases, and percutaneous ultrasound guided RFA in 26 cases. The therapeutic efficacy was evaluated by means of three-phase dynamic abdominal computed tomography (CT) performed within at least one week after ablating. The recurrence was evaluated after treatment by means of abdominal CT and alpha fetoprotein every 3 months. We calculated cumulative recurrence rates, survival rates of patients, and found out complication of RFA.

Results: Cumulative recurrence rates in 3, 6, 12 months after RFA was 8.8%, 15.8%, 25.9%. 12 cases were recurred during follow-up. Among them, intrahepatic recurrences were noted in 11 cases, local recurrences in 3 cases. Cumulative survival curves indicated that survival rate was 95% at the third month, 94% at the sixth month, 81% at the twelfth month. After RFA, the alpha fetoprotein level was decreased significantly after 1 month (p<0.05), and serum transaminase levels were transiently elevated (p<0.01) but returned to normal within one week. Complications of RFA were not serious, and resolved spontaneously.

Conclusion: RFA can be considered a useful new treatment for HCC. Laparoscopic RFA is a useful procedure for the treatment of HCC regardless of its location.

背景/目的:射频消融(RFA)正在成为治疗肝细胞癌(HCC)的一种新的治疗方法。我们报告了64例患者的随访时间为3至19个月的结果。方法:64例82例结节行超声引导下射频消融术。肿瘤平均直径为2.5±1.0 cm。腹腔镜超声引导下RFA 38例,经皮超声引导下RFA 26例。治疗效果通过在消融后至少一周内进行的三相动态腹部计算机断层扫描(CT)来评估。治疗后每3个月通过腹部CT和甲胎蛋白检查评估复发情况。计算患者的累计复发率、生存率,并发现RFA的并发症。结果:术后3、6、12个月的累计复发率分别为8.8%、15.8%、25.9%。随访中12例复发。其中肝内复发11例,局部复发3例。累积生存曲线显示,第3个月生存率为95%,第6个月生存率为94%,第12个月生存率为81%。RFA术后1个月甲胎蛋白水平明显下降(p)结论:RFA是一种有效的治疗HCC的新方法。腹腔镜RFA是治疗HCC的有效方法,无论其位置如何。
{"title":"[Laparoscopic and percutaneous ultrasound guided radiofrequency ablation for hepatocellular carcinoma: a preliminary study].","authors":"Min Kyu Jung,&nbsp;Jong Hyup Lee,&nbsp;Tae Seok Kim,&nbsp;Hyun Soo Kim,&nbsp;Chang Min Cho,&nbsp;Won Young Tak,&nbsp;Young Oh Kweon,&nbsp;Sung Kook Kim,&nbsp;Yong Hwan Choi,&nbsp;Joon Mo Chung","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Radiofrequency ablation (RFA) is emerging as a new therapeutic method in the management of hepatocellular carcinoma (HCC). We report the results of 64 patients with a follow-up interval of 3 to 19 months.</p><p><strong>Method: </strong>Sixty-four patients with 82 nodules underwent ultrasound guided RFA. The mean tumor diameter was 2.5+/-1.0 cm. Laparoscopic ultrasound guided RFA was performed in 38 cases, and percutaneous ultrasound guided RFA in 26 cases. The therapeutic efficacy was evaluated by means of three-phase dynamic abdominal computed tomography (CT) performed within at least one week after ablating. The recurrence was evaluated after treatment by means of abdominal CT and alpha fetoprotein every 3 months. We calculated cumulative recurrence rates, survival rates of patients, and found out complication of RFA.</p><p><strong>Results: </strong>Cumulative recurrence rates in 3, 6, 12 months after RFA was 8.8%, 15.8%, 25.9%. 12 cases were recurred during follow-up. Among them, intrahepatic recurrences were noted in 11 cases, local recurrences in 3 cases. Cumulative survival curves indicated that survival rate was 95% at the third month, 94% at the sixth month, 81% at the twelfth month. After RFA, the alpha fetoprotein level was decreased significantly after 1 month (p<0.05), and serum transaminase levels were transiently elevated (p<0.01) but returned to normal within one week. Complications of RFA were not serious, and resolved spontaneously.</p><p><strong>Conclusion: </strong>RFA can be considered a useful new treatment for HCC. Laparoscopic RFA is a useful procedure for the treatment of HCC regardless of its location.</p>","PeriodicalId":85610,"journal":{"name":"Taehan Kan Hakhoe chi = The Korean journal of hepatology","volume":"8 2","pages":"209-17"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22170890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[An experimental model of hepatic fibrosis induced by alcohol and CCl4: can the lipopolysaccharide prevent liver injury induced by alcohol and CCl4?]. [酒精和CCl4致肝纤维化实验模型:脂多糖能否预防酒精和CCl4致肝损伤?]。
Hee Bok Chae, Lee Chan Jang, Seon Mee Park, Bo Ra Son, Rohyun Sung, Jae Woon Choi

Background/aims: It is well known that alcohol enhances the toxicity of CCl4. We tried to establish an alcoholic liver cirrhosis model by administration of alcohol and CCl4 to rats. We also wanted to know the hepatoprotective effect of low doses of lipopolysaccharide(LPS) in this animal model.

Methods: Of 20 female adult rats, 8 were ingested with alcohol ad libitum(group 1) Another 6 were ingested with 10% alcohol and 50% 1mL/kg CCl4 intragastrically by Sonde twice a week(group 2) The remaining 6 were ingested with 10% alcohol, CCl4, and 0.1mg/kg LPS intraperitoneally twice a week(group 3) The fibrosis was evaluated semiquantitatively on a scale of 0(none) to 3(cirrhosis).

Results: 1) After 10 weeks, septal fibrosis or cirrhosis was produced in 9 out of 12 rats in groups 2 and 3 but there was no fibrotic change in group 1. 2) There was no significant difference in pathological grading between groups 2 and 3.

Conclusions: Hepatic fibrosis or cirrhosis can be sufficiently induced by alcohol and repetitive CCl4 ingestion for 10 weeks. We can not prove the hepatoprotective effect of low dose LPS by semiquantitative evaluation of pathological grading.

背景/目的:众所周知,酒精可增强CCl4的毒性。我们试图通过给药酒精和CCl4建立大鼠酒精性肝硬化模型。我们还想知道低剂量脂多糖(LPS)在动物模型中的肝保护作用。方法:雌性成年大鼠20只,8只自由酒精灌胃(1组),6只Sonde腹腔灌胃10%酒精和50% CCl4 1mL/kg(2组),其余6只腹腔灌胃10%酒精、CCl4和0.1mg/kg LPS, 1周2次(3组),按0(无)~ 3(肝硬化)进行半定量评价。结果:1)10周后,2、3组12只大鼠中有9只出现间隔纤维化或肝硬化,1组无纤维化改变。2) 2组和3组的病理分级无显著差异。结论:连续10周反复摄入CCl4可充分诱导肝纤维化或肝硬化。我们不能通过病理分级的半定量评价来证明低剂量LPS的肝保护作用。
{"title":"[An experimental model of hepatic fibrosis induced by alcohol and CCl4: can the lipopolysaccharide prevent liver injury induced by alcohol and CCl4?].","authors":"Hee Bok Chae,&nbsp;Lee Chan Jang,&nbsp;Seon Mee Park,&nbsp;Bo Ra Son,&nbsp;Rohyun Sung,&nbsp;Jae Woon Choi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>It is well known that alcohol enhances the toxicity of CCl4. We tried to establish an alcoholic liver cirrhosis model by administration of alcohol and CCl4 to rats. We also wanted to know the hepatoprotective effect of low doses of lipopolysaccharide(LPS) in this animal model.</p><p><strong>Methods: </strong>Of 20 female adult rats, 8 were ingested with alcohol ad libitum(group 1) Another 6 were ingested with 10% alcohol and 50% 1mL/kg CCl4 intragastrically by Sonde twice a week(group 2) The remaining 6 were ingested with 10% alcohol, CCl4, and 0.1mg/kg LPS intraperitoneally twice a week(group 3) The fibrosis was evaluated semiquantitatively on a scale of 0(none) to 3(cirrhosis).</p><p><strong>Results: </strong>1) After 10 weeks, septal fibrosis or cirrhosis was produced in 9 out of 12 rats in groups 2 and 3 but there was no fibrotic change in group 1. 2) There was no significant difference in pathological grading between groups 2 and 3.</p><p><strong>Conclusions: </strong>Hepatic fibrosis or cirrhosis can be sufficiently induced by alcohol and repetitive CCl4 ingestion for 10 weeks. We can not prove the hepatoprotective effect of low dose LPS by semiquantitative evaluation of pathological grading.</p>","PeriodicalId":85610,"journal":{"name":"Taehan Kan Hakhoe chi = The Korean journal of hepatology","volume":"8 2","pages":"173-8"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22170886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection]. [韩国慢性乙型肝炎病毒感染患者前、核心启动子突变的患病率及临床意义]。
Hyung Joon Kim, Byung Chul Yoo

Background/aims: Precore and core promoter mutations of hepatitis B virus (HBV) have been reported in Korea but their prevalence and clinical significance have not been determined. The aims of this study were to determine the prevalence of precore and core promoter mutations and their relationships to hepatitis B e antigen (HBeAg) status, viral replication level, and severity of liver disease in Korea.

Methods: Among the patients who visited the Liver Diseases Clinics (Chung Ang University Hospital) between December 1998 and August 1999, 150 patients were randomly selected: 50 HBeAg-positive HBV-DNA positive patients by a branched DNA (bDNA) assay, 50 HBeAg-negative bDNA-positive patients, and 50 HBeAg-negative bDNA-negative patients. Serum HBV-DNA was amplified by a polymerase chain reaction (PCR) in these patients and the core promoter/precore HBV sequence was determined in 135 of the patients whose sera were positive for HBV-DNA by PCR.

Results: All of the 135 determined HBV-DNA sequences had HBV genotype with T at nucleotide 1858. Precore mutation (A1896) was detected in 95.7% of HBeAg-negative bDNA-positive patients and 94.9% of HBeAg-negative bDNA-negative patients. In HBeAg-positive patients 88% had wild type and 12% had mixture of wild type and A1896 mutant. Core promoter TA mutation (T1762/A1764) was detected in 93.5% of HBeAg-negative bDNA-positive patients, 94.9% of HBeAg-negative bDNA-negative patients and 74% of HBeAg-positive patients. No correlation was found between the presence of precore/core promoter mutations and liver disease severity or HBV-DNA levels.

Conclusion: Precore stop codon mutation occurred almost invariably, along with HBeAg seroconversion, irrespective of subsequent viral replication levels or disease severity. Core promoter TA mutation was frequent both in the HBeAg-positive patients and HBeAg-negative patients irrespective of viral replication levels or disease severity.

背景/目的:韩国报道了乙型肝炎病毒(HBV)的前启动子和核心启动子突变,但其患病率和临床意义尚未确定。本研究的目的是确定韩国前核和核心启动子突变的患病率及其与乙型肝炎e抗原(HBeAg)状态、病毒复制水平和肝脏疾病严重程度的关系。方法:从1998年12月至1999年8月在中央大学附属医院肝病门诊就诊的患者中随机抽取150例:hbeag -DNA分支检测阳性患者50例,hbeag -DNA阴性患者50例,hbeag -DNA阴性患者50例。用聚合酶链反应(PCR)扩增这些患者的血清HBV- dna,并在135例HBV- dna阳性的患者中测定核心启动子/前核HBV序列。结果:135例HBV- dna序列均为含T核苷酸1858的HBV基因型。95.7%的hbeag阴性bdna阳性患者和94.9%的hbeag阴性bdna阴性患者检出前体细胞突变(A1896)。hbeag阳性患者88%为野生型,12%为野生型和A1896突变体的混合。hbeag阴性bdna阳性患者中93.5%、hbeag阴性bdna阴性患者中94.9%、hbeag阳性患者中74%检测到核心启动子TA突变(T1762/A1764)。未发现前核/核心启动子突变的存在与肝脏疾病严重程度或HBV-DNA水平之间存在相关性。结论:无论随后的病毒复制水平或疾病严重程度如何,HBeAg血清转换几乎总是发生前停止密码子突变。无论病毒复制水平或疾病严重程度如何,核心启动子TA突变在hbeag阳性患者和hbeag阴性患者中都很常见。
{"title":"[The prevalence and clinical significance of precore and core promoter mutations in Korean patients with chronic hepatitis B virus infection].","authors":"Hyung Joon Kim,&nbsp;Byung Chul Yoo","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/aims: </strong>Precore and core promoter mutations of hepatitis B virus (HBV) have been reported in Korea but their prevalence and clinical significance have not been determined. The aims of this study were to determine the prevalence of precore and core promoter mutations and their relationships to hepatitis B e antigen (HBeAg) status, viral replication level, and severity of liver disease in Korea.</p><p><strong>Methods: </strong>Among the patients who visited the Liver Diseases Clinics (Chung Ang University Hospital) between December 1998 and August 1999, 150 patients were randomly selected: 50 HBeAg-positive HBV-DNA positive patients by a branched DNA (bDNA) assay, 50 HBeAg-negative bDNA-positive patients, and 50 HBeAg-negative bDNA-negative patients. Serum HBV-DNA was amplified by a polymerase chain reaction (PCR) in these patients and the core promoter/precore HBV sequence was determined in 135 of the patients whose sera were positive for HBV-DNA by PCR.</p><p><strong>Results: </strong>All of the 135 determined HBV-DNA sequences had HBV genotype with T at nucleotide 1858. Precore mutation (A1896) was detected in 95.7% of HBeAg-negative bDNA-positive patients and 94.9% of HBeAg-negative bDNA-negative patients. In HBeAg-positive patients 88% had wild type and 12% had mixture of wild type and A1896 mutant. Core promoter TA mutation (T1762/A1764) was detected in 93.5% of HBeAg-negative bDNA-positive patients, 94.9% of HBeAg-negative bDNA-negative patients and 74% of HBeAg-positive patients. No correlation was found between the presence of precore/core promoter mutations and liver disease severity or HBV-DNA levels.</p><p><strong>Conclusion: </strong>Precore stop codon mutation occurred almost invariably, along with HBeAg seroconversion, irrespective of subsequent viral replication levels or disease severity. Core promoter TA mutation was frequent both in the HBeAg-positive patients and HBeAg-negative patients irrespective of viral replication levels or disease severity.</p>","PeriodicalId":85610,"journal":{"name":"Taehan Kan Hakhoe chi = The Korean journal of hepatology","volume":"8 2","pages":"149-56"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22169755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Taehan Kan Hakhoe chi = The Korean journal of hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1